Logo
x

Search

Subscribe Now

RMAT

Audentes Reports Next Phase Development of AT132 for X-linked Myotubular Myopathy (XLMTM) with RMAT Designation

Audentes Reports Next Phase Development of AT132 for X-linked Myotubular Myopathy (XLMTM) with RMAT Designation

  • February 1, 2019
Galderma’ Nemluvio Receives UK’s MHRA & Swissmedic Approval for Atopic Dermatitis and Prurigo Nodularis

    Galderma’ Nemluvio Receives UK’s MHRA & Swissmedic Approval for Atopic Dermatitis and Prurigo Nodularis

    • February 18, 2025
    Galderma’s Nemluvio (Nemolizumab) Secures the EU Approval to Treat Moderate-To-Severe Atopic Dermatitis (AD) and Prurigo nodularis (PN)

      Galderma’s Nemluvio (Nemolizumab) Secures the EU Approval to Treat Moderate-To-Severe Atopic Dermatitis (AD) and Prurigo nodularis...

      • February 14, 2025
      The US FDA grants RMAT Designation to Gradalis’ Vigil for Advanced Ovarian Cancer

        The US FDA grants RMAT Designation to Gradalis’ Vigil for Advanced Ovarian Cancer

        • February 6, 2025
        A Complete Account of FDA Approvals in 2024

          A Complete Account of FDA Approvals in 2024

          • February 5, 2025
          Intelligent Automation and Beyond: Dale Curtis Jr from Astrix in an Enlightening Conversation with PharmaShots

            Intelligent Automation and Beyond: Dale Curtis Jr from Astrix in an Enlightening Conversation with PharmaShots

            • January 31, 2025
            EMA Marketing Authorization of New Drugs in December 2024

              EMA Marketing Authorization of New Drugs in December 2024

              • January 23, 2025
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.